These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35143356)

  • 21. The Importance of Advancing Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Children.
    Kao CM; Orenstein WA; Anderson EJ
    Clin Infect Dis; 2021 Feb; 72(3):515-518. PubMed ID: 33527122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of COVID-19 infection among prison staff in the United States.
    Nowotny KM; Seide K; Brinkley-Rubinstein L
    BMC Public Health; 2021 Jun; 21(1):1036. PubMed ID: 34078350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination Is the Only Acceptable Path to Herd Immunity.
    Rasmussen AL
    Med; 2020 Dec; 1(1):21-23. PubMed ID: 33521750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold.
    Gomes MGM; Ferreira MU; Corder RM; King JG; Souto-Maior C; Penha-Gonçalves C; Gonçalves G; Chikina M; Pegden W; Aguas R
    J Theor Biol; 2022 May; 540():111063. PubMed ID: 35189135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity.
    Chun JY; Jeong H; Kim Y
    J Korean Med Sci; 2021 Oct; 36(38):e272. PubMed ID: 34609093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 in the California State Prison System: an Observational Study of Decarceration, Ongoing Risks, and Risk Factors.
    Chin ET; Ryckman T; Prince L; Leidner D; Alarid-Escudero F; Andrews JR; Salomon JA; Studdert DM; Goldhaber-Fiebert JD
    J Gen Intern Med; 2021 Oct; 36(10):3096-3102. PubMed ID: 34291377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge.
    Papachristodoulou E; Kakoullis L; Parperis K; Panos G
    Pathog Dis; 2020 Apr; 78(3):. PubMed ID: 32510562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Great Expectations of COVID-19 Herd Immunity.
    Giurgea LT; Morens DM
    mBio; 2022 Feb; 13(1):e0349521. PubMed ID: 35073740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analyses of Confirmed COVID-19 Cases Among Korean Military Personnel After Mass Vaccination.
    Shin DH; Oh HS; Jang H; Lee S; Choi BS; Kim D
    J Korean Med Sci; 2022 Jan; 37(3):e23. PubMed ID: 35040298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determining the Prevalence and Incidence of SARS-CoV-2 Infection in Prisons in England: Protocol for a Repeated Panel Survey and Enhanced Outbreak Study.
    Plugge E; Burke D; Czachorowski M; Gutridge K; Maxwell F; McGrath N; O'Mara O; O'Moore E; Parkes J
    JMIR Res Protoc; 2022 Jan; 11(1):e30749. PubMed ID: 34751157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Herd Immunity: Understanding COVID-19.
    Randolph HE; Barreiro LB
    Immunity; 2020 May; 52(5):737-741. PubMed ID: 32433946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe acute respiratory syndrome-coronavirus-2 seroprevalence study in Pimpri-Chinchwad, Maharashtra, India coinciding with falling trend - Do the results suggest imminent herd immunity?
    Banerjee A; Gaikwad B; Desale A; Jadhav SL; Rathod H; Srivastava K
    Indian J Public Health; 2021; 65(3):256-260. PubMed ID: 34558487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 herd immunity in the absence of a vaccine: an irresponsible approach.
    Khalife J; VanGennep D
    Epidemiol Health; 2021; 43():e2021012. PubMed ID: 33541010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.
    Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N
    Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timeliness and obsolescence of herd immunity threshold estimates in the COVID-19 pandemic.
    Gomes MGM
    Public Health; 2022 Apr; 205():e3-e4. PubMed ID: 34756588
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19 community spread and consequences for prison case rates.
    LeMasters K; Ranapurwala S; Maner M; Nowotny KM; Peterson M; Brinkley-Rubinstein L
    PLoS One; 2022; 17(4):e0266772. PubMed ID: 35417500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
    Mveang Nzoghe A; Leboueny M; Kuissi Kamgaing E; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Padzys GS; Ndeboko B; Ategbo S; Djoba Siawaya JF
    BMC Res Notes; 2021 Apr; 14(1):152. PubMed ID: 33879229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 and immunity: quo vadis?
    Miyasaka M
    Int Immunol; 2021 Sep; 33(10):507-513. PubMed ID: 33569606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.